TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02265224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: The product was administered according to the randomisation list and cross-over design, with 150 mL of still mineral water under fasting conditions on study day 1 of periods 1 or 2 at 8:00±1 h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: The product was administered according to the randomisation list and cross-over design, with 150 mL of still mineral water under fasting conditions on study day 1 of periods 1 or 2 at 8:00±1 h.
Study: NCT02710760

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adoption Encouragement Treatment
Description: Households in the Adoption Encouragement Treatment received child nutrition focused guidance on the nutritional and agronomic benefits of Quality Protein Maize (QPM) adoption, and the opportunity to order up to 6 kg of QPM seed to plant in their own fields.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adoption Encouragement Treatment
Description: Households in the Adoption Encouragement Treatment received child nutrition focused guidance on the nutritional and agronomic benefits of Quality Protein Maize (QPM) adoption, and the opportunity to order up to 6 kg of QPM seed to plant in their own fields.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consumption Encouragement Treatment
Description: Households in the Consumption Encouragement Treatment received the same guidance as households in the Adoption Encouragement Treatment, as well as additional guidance on the importance of specifically targeting foods made with QPM to young children and tools to help households keep the grain separate and remember to feed QPM-based foods to the young children.
Study: NCT03775408

Intervention type: DEVICE
Intervention: FAST
Description: Orthopaedic surgeons will use the FAST device to facilitate entry point selection and alignment of a guidewire for intramedullary nailing of femoral shaft fractures.
Study: NCT00584805

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated, Dried, TSI-GSD 104, EEE
Description: Subjects will receive 0.5ml SQ, as a two-dose primary series (days 0 and 28) and 0.1ml, as a mandatory booster dose at 6 months. A booster dose may be administered before 6 months if PRNT80 is \< 1:40 after day 28. Up to four booster doses may be given in any 1-year period.
Study: NCT02006420

Intervention type: DEVICE
Intervention: ARFI-SVI Ultrasound
Description: Ultrasound imaging of arm and leg lasting approximately 5-10 minutes. Participants will also undergo durometer scoring on the forearm and thigh as part of the study. This lasts approximately 5-10 minutes.

Intervention type: DEVICE
Intervention: ARFI-SVI Ultrasound
Description: Ultrasound imaging of arm and leg lasting approximately 5-10 minutes. Participants will also undergo durometer scoring on the forearm and thigh as part of the study. This lasts approximately 5-10 minutes.
Study: NCT02025920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salmon Group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cod Group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meat Group
Study: NCT02691104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMART COPD app to promote physical activity in COPD. Used in conjunction with a Fitbit Charge
Description: An app which allows users to set physical activity goals, monitors progress towards those goals, and provides feedback to users. Several options for types of physical activity (daily walk, daily step count, and aerobic / strengthening exercises) which can be tailored to the individual user. Designed to be used in consultation with a physiotherapist initially, and then used independently by the individual with COPD. The app will first be used alongside pulmonary rehabilitation (PR), with physiotherapist advice on exercises and setting goals. After PR the individual with COPD will receive weekly contact from a physiotherapist for the first 4 weeks, and then no contact for the second 4 weeks

Intervention type: DEVICE
Group type: OTHER
Intervention: Control
Description: Participants will follow the (usual care) PR programme. They will be asked to wear a blinided (cannot see step count) Fitbit Charge during the time they are on PR and then for 8 weeks afterwards
Study: NCT03022838

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: From the point of enrollment, patients will substitute their daily dietary caffeine with either placebo- or capsulated caffeine tablets (Recip®, 100mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine
Description: From the point of enrollment, patients will substitute their daily dietary caffeine with either placebo- or capsulated caffeine tablets (Recip®, 100mg).
Study: NCT03096171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flourishing App Program
Description: This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 16 weeks, with trainings of 20 minutes, four times a week.
Study: NCT02312180

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasminogen (Human) Intravenous
Description: Plasma-derived purified plasminogen formulated for intravenous administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasminogen (Human) Intravenous
Description: Plasma-derived purified plasminogen formulated for intravenous administration
Study: NCT04307498

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intensive Outpatient Program - Prolonged Exposure
Description: Prolonged Exposure for Posttraumatic Stress Disorder (PE for PTSD; Foa, Hembree, \& Rothbaum, 2007) is an empirically supported behavioral therapy that utilizes exposure-based interventions to target the psychological mechanisms (i.e., avoidance; maladaptive cognitive changes) thought to maintain trauma-related symptoms. IOP-PE includes 15 days of PE treatment delivered over three consecutive weeks. The standard outpatient PE protocol has modified with seven treatment augmentations to meet the unique needs of post-9/11 veterans.
Study: NCT02894996

Intervention type: DRUG
Group type: OTHER
Intervention: fluid challenge
Description: fluid challenge realized after induction of anesthesia at a steady state, to assess fluid responsiveness and correct hypovolemia. The usual fluid bolus of 15ml/kg in 10 minute will be fragmented in 2 fluid boluses (3ml/kg in 2 minutes followed by measurement of hemodynamic parameter after 1 minute of the end of the 1st fluid bolus and followed by 12 ml/kg in 8 minutes then followed by measurement of hemodynamic parameters after one minute after the end of the 2nd fluid fragmented fluid challenge. Total administered: 15 ml/kg in 11 minutes. end of the study at 12 minutes.
Study: NCT03786120

Intervention type: DRUG
Intervention: Zolpidem
Description: PO sleep aid in various doses

Intervention type: DRUG
Intervention: Zolpidem
Description: PO sleep aid in various doses
Study: NCT02544269

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Lumbosacral plexus blockade with ropivacaine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Regional anesthesia with bupivacaine titrated to the lowest effective dose
Study: NCT04145089

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope video laryngoscopy/ C-MAC video laryngoscopy
Description: usage of said devices according to manual

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope video laryngoscopy/ C-MAC video laryngoscopy
Description: usage of said devices according to manual
Study: NCT02511314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENA Identifi
Description: TENA Identifi
Study: NCT02070731

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriGuard HDH
Description: TAVI with the TriGuard HDH embolic deflection device
Study: NCT02624245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Study: NCT03343717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: physical therapy exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chest physical therapy
Description: chest physical therapy exercise
Study: NCT04029363

Intervention type: DEVICE
Group type: OTHER
Intervention: HighLife Transcatheter Mitral Valve Replacement
Description: Transcatheter Mitral Valve Replacement
Study: NCT02416193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Participants will take randomly assigned high dose cholecalciferol once weekly for three months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Participants will take randomly assigned active comparator cholecalciferol once weekly for three months
Study: NCT03470012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-Purpose Gentle Tape
Description: The Multi-Purpose Gentle Tape is a general purpose medical adhesive tape for medical applications used primarily to secure dressings, lightweight tubing, and devices to skin.
Study: NCT05871398

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegoprazan
Description: Novel, potent, and highly selective potassium-competitive acid blocker which was developed in Korea

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01513109

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)
Description: i.m. administration
Study: NCT03470558

Intervention type: OTHER
Intervention: Dietary habits
Description: Sleeve gastrectomy patients will be asked to monitor dietary habits before surgery and at 2, 6, and 12 months after surgery.
Study: NCT04634812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074
Description: a single oral dose of \[14C\]-KBP-5074
Study: NCT04766489

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Complete Decongtestive Therapy
Description: Patients will be given complete decongestive therapy, which includes decongestive exercises, manual lymphatic drainage, compression therapy(either through short stretch bandaging and/or pneumatic device) and exercise, for 5 days a week and for a mean of 20 sessions. Each session will be of 1 hour duration for compressive therapies(Short stretch bandages will be left on for 23 hours a day), 30 minutes of manual lymphatic drainage, and decongestive exercises 3 times a day for 15 minutes each time.
Study: NCT01869621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 6 days treatment with metformin to steady-state
Study: NCT03726203

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laparoscopic gynecologic surgery with the MiniLap System.
Description: Subjects participating in the study will undergo laparoscopic gynecologic surgery as planned in the routine care, but using the MiniLap System instead of the conventional single-use trocars used usually.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic gynecologic surgery with the conventional single-use trocars.
Description: Subjects participating in the study will undergo laparoscopic gynecologic surgery as planned in the routine care using the conventional single-use trocars used usually.
Study: NCT03640975

Intervention type: OTHER
Intervention: Endoscopy
Description: The endoscopy will be performed under general anaesthesia using a flexible endoscope with an external diameter of between 4.9 and 9.2 mm, depending on the size of the child. In line with the guidelines, eight biopsies will be collected from the proximal, median and distal oesophagus for the routine analysis of esophageal remodelling and inflammation. Three of these biopsies will be used in the context of this study to analyse innate immune cells using flow cytometry and to determine the profile of cytokine expression. Two biopsies will be placed in sterile, 0.5 ml Nunc tubes containing a storage buffer (MACS® Tissue Storage Solution) and then stored in ice until the extraction of cells for cytometric analysis . The third specimen will be placed in a sterile tube and frozen immediately in liquid nitrogen for analyses of the esophageal microbiome.

Intervention type: OTHER
Intervention: Endoscopy
Description: The endoscopy will be performed under general anaesthesia using a flexible endoscope with an external diameter of between 4.9 and 9.2 mm, depending on the size of the child. In line with the guidelines, eight biopsies will be collected from the proximal, median and distal oesophagus for the routine analysis of esophageal remodelling and inflammation. Three of these biopsies will be used in the context of this study to analyse innate immune cells using flow cytometry and to determine the profile of cytokine expression. Two biopsies will be placed in sterile, 0.5 ml Nunc tubes containing a storage buffer (MACS® Tissue Storage Solution) and then stored in ice until the extraction of cells for cytometric analysis . The third specimen will be placed in a sterile tube and frozen immediately in liquid nitrogen for analyses of the esophageal microbiome.
Study: NCT02985606

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine powder -60

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine powder -30

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine powder 0

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo powder -60

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo powder -60

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder -60

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo powder -30

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo powder -30

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder -30

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo powder 0

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo powder 0

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder 0
Study: NCT04384861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mayo Clinic SMART program (Stress Management and Resilience Training)
Description: The SMART program included a workshop and ongoing eLearning Support. The learning objectives of the workshop are: (1) learn the neuroscience and behavioural aspects of human experience, particularly with respect to stress, resiliency, performance and wellness and (2) learn practical approaches to enhance engagement and emotional intelligence and thereby decrease stress and anxiety, increase resilience, enhance performance, and improve relationships. The goal of the eLearning support is to support and reinforce the messages and techniques delivered in the 2-hour workshop.
Study: NCT03694418

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: We are here now: a multi-level, multi-component sexual and reproductive health intervention for American Indian youth
Description: N/E will be implemented simultaneously over the 9-month school year. Components include: 1) Individual Level- Native Stand 2) Family Level - Native Voices; 3) Community Level - Cultural mentoring program; and 4) Systems Level. The fourth level of N/E mobilizes the existing Epidemiology Team to enhance the coordination and implementation of SRH services at Fort Peck.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: We are here now: a multi-level, multi-component sexual and reproductive health intervention for American Indian youth
Description: N/E will be implemented simultaneously over the 9-month school year. Components include: 1) Individual Level- Native Stand 2) Family Level - Native Voices; 3) Community Level - Cultural mentoring program; and 4) Systems Level. The fourth level of N/E mobilizes the existing Epidemiology Team to enhance the coordination and implementation of SRH services at Fort Peck.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: We are here now: a multi-level, multi-component sexual and reproductive health intervention for American Indian youth
Description: N/E will be implemented simultaneously over the 9-month school year. Components include: 1) Individual Level- Native Stand 2) Family Level - Native Voices; 3) Community Level - Cultural mentoring program; and 4) Systems Level. The fourth level of N/E mobilizes the existing Epidemiology Team to enhance the coordination and implementation of SRH services at Fort Peck.
Study: NCT03150654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser pan-retinal photocoagulation
Description: Green laser photocoagulator
Study: NCT00858299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan
Description: 160 mg oral once in a day for initial 8 weeks and 320 mg, oral, once in a day for subsequent 16 weeks
Study: NCT01878812

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix/Influsplit Tetra® (2013-2014 season)
Description: 1 dose administered intramuscularly in the deltoid region of non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix/Influsplit Tetra® (2013-2014 season)
Description: 1 dose administered intramuscularly in the deltoid region of non-dominant arm
Study: NCT02988440

Intervention type: DRUG
Group type: OTHER
Intervention: PDR001
Description: PDR001 will be administered intravenously

Intervention type: DRUG
Group type: OTHER
Intervention: Sorafenib
Description: Sorafenib is formulated as a tablet.
Study: NCT02220179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Resilience Program
Description: Se the CONSORT trial protocol at http://myresilience.org/ at the subsite 'about us'

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Resilience Program
Description: Se the CONSORT trial protocol at http://myresilience.org/ at the subsite 'about us'
Study: NCT02520427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 330
Description: 0.5 µg/day - 1.6 mg/day cIV infusion administered in cycles from 14 to 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 330
Description: 0.5 µg/day - 1.6 mg/day cIV infusion administered in cycles from 14 to 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 330
Description: 0.5 µg/day - 1.6 mg/day cIV infusion administered in cycles from 14 to 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 330
Description: 0.5 µg/day - 1.6 mg/day cIV infusion administered in cycles from 14 to 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 330
Description: 0.5 µg/day - 1.6 mg/day cIV infusion administered in cycles from 14 to 28 days.
Study: NCT02031640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone dipropionate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone dipropionate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol
Description: Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol/salbutamol
Description: Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol
Description: Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol/salbutamol
Description: Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol/salbutamol
Description: Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.
Study: NCT00720512

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study: NCT02459847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sonographic Biofeedback

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Study: NCT01795092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dermatology Consultation
Description: A dermatology consultation will be conducted on patients randomized to this group.